Crinetics Pharmaceuticals, Inc. Income (Loss) from Continuing Operations before Income Taxes, Domestic
Crinetics Pharmaceuticals, Inc. (CRNX) reported Income (Loss) from Continuing Operations before Income Taxes, Domestic of -$453.63 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Income Statement › Pre-tax Income
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic · last filed 2026-02-26
- Crinetics Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2025 was -$453.63M.
- Crinetics Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2024 was -$297.44M.
- Crinetics Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2023 was -$208.83M.
- Crinetics Pharmaceuticals, Inc. income (loss) from continuing operations before income taxes, domestic for fiscal 2022 was -$163.18M.
| Period end | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month | Income (Loss) from Continuing Operations before Income Taxes, Domestic 12 month as first filed |
|---|---|---|
| 2025-12-31 | -$453.63M 10-K · filed 2026-02-26 | |
| 2024-12-31 | -$297.44M 10-K · filed 2026-02-26 | -$297.91M 10-K · filed 2025-02-27 |
| 2023-12-31 | -$208.83M 10-K · filed 2026-02-26 | -$214.03M 10-K · filed 2024-02-28 |
| 2022-12-31 | -$163.18M 10-K · filed 2025-02-27 | |
| 2021-12-31 | -$107.72M 10-K · filed 2024-02-28 | |
| 2020-12-31 | -$71.77M 10-K · filed 2023-02-28 | |
| 2019-12-31 | -$48.64M 10-K · filed 2022-03-30 | |
| 2018-12-31 | -$25.88M 10-K · filed 2021-03-30 | |
| 2017-12-31 | -$8.14M 10-K · filed 2020-03-09 | |
| 2016-12-31 | -$6.02M 10-K · filed 2019-03-13 |